메뉴 건너뛰기




Volumn 19, Issue 8, 2017, Pages 1106-1115

Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials

Author keywords

meta analysis; renal outcomes; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85017337183     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12917     Document Type: Article
Times cited : (66)

References (46)
  • 1
    • 84864283226 scopus 로고    scopus 로고
    • SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
    • Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 495-502
    • Ferrannini, E.1    Solini, A.2
  • 2
    • 84899904943 scopus 로고    scopus 로고
    • Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action
    • Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5:265-275.
    • (2014) J Diabetes Investig , vol.5 , pp. 265-275
    • Fujita, Y.1    Inagaki, N.2
  • 3
    • 64749099761 scopus 로고    scopus 로고
    • Glucose control by the kidney: an emerging target in diabetes
    • Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875-883.
    • (2009) Am J Kidney Dis , vol.53 , pp. 875-883
    • Marsenic, O.1
  • 4
    • 84882251091 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis
    • Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
    • (2013) Ann Intern Med , vol.159 , pp. 262-274
    • Vasilakou, D.1    Karagiannis, T.2    Athanasiadou, E.3
  • 5
    • 84898791935 scopus 로고    scopus 로고
    • Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
    • Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457-466.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 457-466
    • Monami, M.1    Nardini, C.2    Mannucci, E.3
  • 6
    • 84898854471 scopus 로고    scopus 로고
    • Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis
    • Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262-275.e9.
    • (2014) J Am Soc Hypertens , vol.8 , pp. 262-275.e9
    • Baker, W.L.1    Smyth, L.R.2    Riche, D.M.3    Bourret, E.M.4    Chamberlin, K.W.5    White, W.B.6
  • 7
    • 84955608712 scopus 로고    scopus 로고
    • The role of the kidney and SGLT2 inhibitors in Type 2 diabetes
    • Katz PM, Leiter LA. The role of the kidney and SGLT2 inhibitors in Type 2 diabetes. Can J Diabetes. 2015;39(suppl 5):S167-S175.
    • (2015) Can J Diabetes , vol.39 , pp. S167-S175
    • Katz, P.M.1    Leiter, L.A.2
  • 8
    • 58449121090 scopus 로고    scopus 로고
    • Changes in blood pressure before the development of nosocomial acute kidney injury
    • Liu YL, Prowle J, Licari E, Uchino S, Bellomo R. Changes in blood pressure before the development of nosocomial acute kidney injury. Nephrol Dial Transplant. 2009;24:504-511.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 504-511
    • Liu, Y.L.1    Prowle, J.2    Licari, E.3    Uchino, S.4    Bellomo, R.5
  • 9
    • 84897394040 scopus 로고    scopus 로고
    • Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
    • Kohan DE, Fioretto P, Tang WH, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
    • (2014) Kidney Int , vol.85 , pp. 962-971
    • Kohan, D.E.1    Fioretto, P.2    Tang, W.H.3    List, J.F.4
  • 10
    • 84930580133 scopus 로고    scopus 로고
    • Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
    • Hinnen D. Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2015;6:92-102.
    • (2015) Ther Adv Endocrinol Metab , vol.6 , pp. 92-102
    • Hinnen, D.1
  • 12
    • 84906924894 scopus 로고    scopus 로고
    • Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results
    • Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16-34.
    • (2014) Postgrad Med , vol.126 , pp. 16-34
    • Usiskin, K.1    Kline, I.2    Fung, A.3    Mayer, C.4    Meininger, G.5
  • 13
    • 84892488179 scopus 로고    scopus 로고
    • Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
    • Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 124-136
    • Wilding, J.P.1    Woo, V.2    Rohwedder, K.3    Sugg, J.4    Parikh, S.5
  • 15
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 16
    • 84932084410 scopus 로고    scopus 로고
    • The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
    • Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777-784.
    • (2015) Ann Intern Med , vol.162 , pp. 777-784
    • Hutton, B.1    Salanti, G.2    Caldwell, D.M.3
  • 17
  • 18
    • 33846260745 scopus 로고    scopus 로고
    • Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
    • Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53-77.
    • (2007) Stat Med , vol.26 , pp. 53-77
    • Bradburn, M.J.1    Deeks, J.J.2    Berlin, J.A.3    Russell Localio, A.4
  • 19
    • 84875612338 scopus 로고    scopus 로고
    • Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
    • White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3:111-125.
    • (2012) Res Synth Methods , vol.3 , pp. 111-125
    • White, I.R.1    Barrett, J.K.2    Jackson, D.3    Higgins, J.P.4
  • 21
    • 61949136504 scopus 로고    scopus 로고
    • Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials
    • Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol. 2009;104:546-551.
    • (2009) Am J Gastroenterol , vol.104 , pp. 546-551
    • Keus, F.1    Wetterslev, J.2    Gluud, C.3    Gooszen, H.G.4    van Laarhoven, C.J.5
  • 22
    • 85164560670 scopus 로고    scopus 로고
    • Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
    • Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80-97.
    • (2012) Res Synth Methods , vol.3 , pp. 80-97
    • Salanti, G.1
  • 23
    • 84864508284 scopus 로고    scopus 로고
    • Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews
    • Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41:818-827.
    • (2012) Int J Epidemiol , vol.41 , pp. 818-827
    • Turner, R.M.1    Davey, J.2    Clarke, M.J.3    Thompson, S.G.4    Higgins, J.P.5
  • 25
    • 84875625927 scopus 로고    scopus 로고
    • Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
    • Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98-110.
    • (2012) Res Synth Methods , vol.3 , pp. 98-110
    • Higgins, J.P.1    Jackson, D.2    Barrett, J.K.3    Lu, G.4    Ades, A.E.5    White, I.R.6
  • 26
    • 0028798488 scopus 로고
    • Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care
    • discussion 59–60
    • Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol. 1995;48:45-57; discussion 59–60.
    • (1995) J Clin Epidemiol , vol.48 , pp. 45-57
    • Lau, J.1    Schmid, C.H.2    Chalmers, T.C.3
  • 27
    • 84880287328 scopus 로고    scopus 로고
    • Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions
    • Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3:161-176.
    • (2012) Res Synth Methods , vol.3 , pp. 161-176
    • Chaimani, A.1    Salanti, G.2
  • 28
    • 84891851923 scopus 로고    scopus 로고
    • Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
    • Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015-4021.
    • (2013) Diabetes Care , vol.36 , pp. 4015-4021
    • Ferrannini, E.1    Berk, A.2    Hantel, S.3
  • 29
    • 84928199102 scopus 로고    scopus 로고
    • Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
    • Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394-402.
    • (2015) Diabetes Care , vol.38 , pp. 394-402
    • Lewin, A.1    DeFronzo, R.A.2    Patel, S.3
  • 30
    • 84928176749 scopus 로고    scopus 로고
    • Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
    • DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384-393.
    • (2015) Diabetes Care , vol.38 , pp. 384-393
    • DeFronzo, R.A.1    Lewin, A.2    Patel, S.3
  • 31
    • 84904466033 scopus 로고    scopus 로고
    • Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension
    • Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252-1262.
    • (2014) J Am Geriatr Soc , vol.62 , pp. 1252-1262
    • Leiter, L.A.1    Cefalu, W.T.2    de Bruin, T.W.3    Gause-Nilsson, I.4    Sugg, J.5    Parikh, S.J.6
  • 32
    • 84934288630 scopus 로고    scopus 로고
    • Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events
    • Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37:815-829.
    • (2014) Drug Saf , vol.37 , pp. 815-829
    • Ptaszynska, A.1    Johnsson, K.M.2    Parikh, S.J.3    de Bruin, T.W.4    Apanovitch, A.M.5    List, J.F.6
  • 33
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5
  • 35
    • 84978402704 scopus 로고    scopus 로고
    • Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
    • Johnsson K, Johnsson E, Mansfield TA, Yavin Y, Ptaszynska A, Parikh SJ. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med. 2016;128:346-355.
    • (2016) Postgrad Med , vol.128 , pp. 346-355
    • Johnsson, K.1    Johnsson, E.2    Mansfield, T.A.3    Yavin, Y.4    Ptaszynska, A.5    Parikh, S.J.6
  • 36
    • 84255185190 scopus 로고    scopus 로고
    • Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
    • Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-R83.
    • (2012) Am J Physiol Regul Integr Comp Physiol , vol.302 , pp. R75-R83
    • Thomson, S.C.1    Rieg, T.2    Miracle, C.3
  • 37
    • 84899961819 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    • Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 369-384
    • Barnett, A.H.1    Mithal, A.2    Manassie, J.3
  • 38
    • 84994180780 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in Type 2 diabetes
    • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med. 2016;375:323-334.
    • (2016) N Engl J Med , vol.375 , pp. 323-334
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 39
    • 84928211935 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibitors and renal function-2
    • Bloomgarden Z. Sodium-glucose cotransporter 2 inhibitors and renal function-2. J Diabetes. 2015;7:295-298.
    • (2015) J Diabetes , vol.7 , pp. 295-298
    • Bloomgarden, Z.1
  • 40
    • 84912527805 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
    • Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016-1027.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 1016-1027
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 41
    • 85007043802 scopus 로고    scopus 로고
    • Association of chronic kidney disease with coronary heart disease and stroke risks in patients with Type 2 diabetes mellitus: an observational cross-sectional study in Hangzhou, China
    • Sun X, He J, Ji XL, et al. Association of chronic kidney disease with coronary heart disease and stroke risks in patients with Type 2 diabetes mellitus: an observational cross-sectional study in Hangzhou, China. Chin Med J (Engl). 2017;130:57-63.
    • (2017) Chin Med J (Engl) , vol.130 , pp. 57-63
    • Sun, X.1    He, J.2    Ji, X.L.3
  • 42
    • 84964289601 scopus 로고    scopus 로고
    • Adverse effects of drugs on the kidney
    • Bartoli E. Adverse effects of drugs on the kidney. Eur J Intern Med. 2016;28:1-8.
    • (2016) Eur J Intern Med , vol.28 , pp. 1-8
    • Bartoli, E.1
  • 43
    • 85017044529 scopus 로고    scopus 로고
    • Accessed August 15, 2016
    • U.S. Food and Drug Administration. Dapagliflozin. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202293s008lbl.pdf. Accessed August 15, 2016.
    • (2015) Dapagliflozin
  • 44
    • 84968819425 scopus 로고    scopus 로고
    • Accessed August 15, 2016
    • U.S. Food and Drug Administration. Canagliflozin. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204042s013lbl.pdf. Accessed August 15, 2016.
    • (2015) Canagliflozin
  • 45
    • 85025124481 scopus 로고    scopus 로고
    • Accessed August 15, 2016
    • U.S. Food and Drug Administration. Empagliflozin. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s004lbl.pdf. Accessed August 15, 2016.
    • (2015) Empagliflozin
  • 46
    • 84962613532 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
    • Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411-419.
    • (2016) Lancet Diabetes Endocrinol , vol.4 , pp. 411-419
    • Wu, J.H.1    Foote, C.2    Blomster, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.